Mounia Beloueche-Babari1, Yann Jamin1, Vaitha Arunan1, Simon Walker-Samuel1, Paul D. Smith2, John C. Waterton2, Jane Halliday2, Martin O. Leach1, Simon P. Robinson1
1Institute of Cancer Research, Sutton, Surrey, United Kingdom; 2AstraZeneca, Macclesfield, Cheshire
Down-modulation of the BRAF-MEK-ERK1/2 signalling pathway is a novel strategy for targeted cancer treatment that causes tumour growth inhibition and induction of apoptosis. Diffusion-weighted MRI was used to detect pharmacodynamic biomarkers of treatment with the MEK inhibitor AZD6244. Treatment of a human melanoma xenograft model with AZD6244 caused inhibition of tumour growth that was associated with an increase in the apparent diffusion coefficient and tumour necrosis.